KR20210124409A - Tyk2 슈도키나제 리간드 - Google Patents
Tyk2 슈도키나제 리간드 Download PDFInfo
- Publication number
- KR20210124409A KR20210124409A KR1020217028660A KR20217028660A KR20210124409A KR 20210124409 A KR20210124409 A KR 20210124409A KR 1020217028660 A KR1020217028660 A KR 1020217028660A KR 20217028660 A KR20217028660 A KR 20217028660A KR 20210124409 A KR20210124409 A KR 20210124409A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutically acceptable
- solvate
- acceptable salt
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *Nc([n]1nc2)cc(Nc(c3c(cc4F)OCCO3)c4F)nc1c2C(NC(C1)C1F)=O Chemical compound *Nc([n]1nc2)cc(Nc(c3c(cc4F)OCCO3)c4F)nc1c2C(NC(C1)C1F)=O 0.000 description 3
- INQZOENGTYJQEU-UHFFFAOYSA-N CCOC(c1n[s]cc1Nc(cc(NC)[n]1nc2)nc1c2C(NCCOC)=O)=O Chemical compound CCOC(c1n[s]cc1Nc(cc(NC)[n]1nc2)nc1c2C(NCCOC)=O)=O INQZOENGTYJQEU-UHFFFAOYSA-N 0.000 description 2
- BPRWTFKULXHICC-UHFFFAOYSA-N CNc([n]1nc2)cc(Nc3c[n](CCOC)nc3)nc1c2C(NC1CC1)=O Chemical compound CNc([n]1nc2)cc(Nc3c[n](CCOC)nc3)nc1c2C(NC1CC1)=O BPRWTFKULXHICC-UHFFFAOYSA-N 0.000 description 2
- XDTLBZUVHDNXKE-UHFFFAOYSA-N CNc([n]1nc2)cc(Nc3c[s]nc3C(O)=O)nc1c2C(NCCOC)=O Chemical compound CNc([n]1nc2)cc(Nc3c[s]nc3C(O)=O)nc1c2C(NCCOC)=O XDTLBZUVHDNXKE-UHFFFAOYSA-N 0.000 description 2
- UJJLIEVCGRLSML-UHFFFAOYSA-N CC(C)(CNC(c(cn[n]1c(NC)c2)c1nc2NC1=CC(F)=CN(C)C1=O)=O)O Chemical compound CC(C)(CNC(c(cn[n]1c(NC)c2)c1nc2NC1=CC(F)=CN(C)C1=O)=O)O UJJLIEVCGRLSML-UHFFFAOYSA-N 0.000 description 1
- HEHMHYKLNYCSEW-UHFFFAOYSA-N CC(C)(CNC(c(cn[n]1c(NC)c2)c1nc2NC1=CC=CN(C)C1=O)=O)O Chemical compound CC(C)(CNC(c(cn[n]1c(NC)c2)c1nc2NC1=CC=CN(C)C1=O)=O)O HEHMHYKLNYCSEW-UHFFFAOYSA-N 0.000 description 1
- DZIMUHJBGVVXOI-UHFFFAOYSA-N CC(C)(CNC(c(cn[n]1c(NC)c2)c1nc2Nc(c1c(cc2)OCO1)c2Cl)=O)CO Chemical compound CC(C)(CNC(c(cn[n]1c(NC)c2)c1nc2Nc(c1c(cc2)OCO1)c2Cl)=O)CO DZIMUHJBGVVXOI-UHFFFAOYSA-N 0.000 description 1
- HRVXLYVSGREXGO-UHFFFAOYSA-N CC(C)(CNC(c(cn[n]1c(NC)c2)c1nc2Nc(c1c(cc2F)OCCO1)c2F)=O)CO Chemical compound CC(C)(CNC(c(cn[n]1c(NC)c2)c1nc2Nc(c1c(cc2F)OCCO1)c2F)=O)CO HRVXLYVSGREXGO-UHFFFAOYSA-N 0.000 description 1
- SBCMSRLLXLQYRL-UHFFFAOYSA-N CC(C)(CNC(c(cn[n]1c(NC)c2)c1nc2Nc(c1c(cc2F)OCCO1)c2F)=O)O Chemical compound CC(C)(CNC(c(cn[n]1c(NC)c2)c1nc2Nc(c1c(cc2F)OCCO1)c2F)=O)O SBCMSRLLXLQYRL-UHFFFAOYSA-N 0.000 description 1
- WMVYACDSAOKKQL-UHFFFAOYSA-N CC(C)(CNC(c(cn[n]1c(NC)c2)c1nc2Nc(cccc1O2)c1OC2(F)F)=O)CO Chemical compound CC(C)(CNC(c(cn[n]1c(NC)c2)c1nc2Nc(cccc1O2)c1OC2(F)F)=O)CO WMVYACDSAOKKQL-UHFFFAOYSA-N 0.000 description 1
- PNMLWVCPQOSHOM-UHFFFAOYSA-N CC(C)(CNC(c(cn[n]1c(NC)c2)c1nc2Nc1cc(F)cc2c1OCCO2)=O)CO Chemical compound CC(C)(CNC(c(cn[n]1c(NC)c2)c1nc2Nc1cc(F)cc2c1OCCO2)=O)CO PNMLWVCPQOSHOM-UHFFFAOYSA-N 0.000 description 1
- MXYOTGRJVRWDQG-UHFFFAOYSA-N CC(C)(CNC(c(cn[n]1c(NC)c2)c1nc2Nc1cccc2c1OCO2)=O)CO Chemical compound CC(C)(CNC(c(cn[n]1c(NC)c2)c1nc2Nc1cccc2c1OCO2)=O)CO MXYOTGRJVRWDQG-UHFFFAOYSA-N 0.000 description 1
- OKCZWHOTIBXRDX-UHFFFAOYSA-N CC(CNC(c(cn[n]1c(NC)c2)c1nc2Nc1cccc2c1OCCO2)=O)(CO)O Chemical compound CC(CNC(c(cn[n]1c(NC)c2)c1nc2Nc1cccc2c1OCCO2)=O)(CO)O OKCZWHOTIBXRDX-UHFFFAOYSA-N 0.000 description 1
- LLGKCETWXCJTRQ-BKPRWIHQSA-N CCOC(C(/C(/Nc(cc(NC)[n]1nc2)nc1c2C(NC1CC1)=O)=C\NC)=N)=O Chemical compound CCOC(C(/C(/Nc(cc(NC)[n]1nc2)nc1c2C(NC1CC1)=O)=C\NC)=N)=O LLGKCETWXCJTRQ-BKPRWIHQSA-N 0.000 description 1
- KYIZWSAVAXHVFG-UHFFFAOYSA-N CCOC(c1c[s]cc1Nc(cc(NC)[n]1nc2)nc1c2C(NC1CC1)=O)=O Chemical compound CCOC(c1c[s]cc1Nc(cc(NC)[n]1nc2)nc1c2C(NC1CC1)=O)=O KYIZWSAVAXHVFG-UHFFFAOYSA-N 0.000 description 1
- DZVONMMCQXJTII-UHFFFAOYSA-N CCOC(c1n[s]cc1Nc(cc(NC)[n]1nc2)nc1c2C(NC1CC1)=O)=O Chemical compound CCOC(c1n[s]cc1Nc(cc(NC)[n]1nc2)nc1c2C(NC1CC1)=O)=O DZVONMMCQXJTII-UHFFFAOYSA-N 0.000 description 1
- CWSDCOIDLPBLDC-UHFFFAOYSA-N CNC(c1c[s]cc1Nc(cc(NC)[n]1nc2)nc1c2C(NC1CC1)=O)=O Chemical compound CNC(c1c[s]cc1Nc(cc(NC)[n]1nc2)nc1c2C(NC1CC1)=O)=O CWSDCOIDLPBLDC-UHFFFAOYSA-N 0.000 description 1
- ZGHBJAAXGMCCQW-UHFFFAOYSA-N CNC(c1n[s]cc1Nc(cc(NC)[n]1nc2)nc1c2C(NC1CC1)=O)=O Chemical compound CNC(c1n[s]cc1Nc(cc(NC)[n]1nc2)nc1c2C(NC1CC1)=O)=O ZGHBJAAXGMCCQW-UHFFFAOYSA-N 0.000 description 1
- HAPOYKFRFWIYAH-UHFFFAOYSA-N CNc([n]1nc2)cc(NC3=CC=CN(C)C3=O)nc1c2C(N)=O Chemical compound CNc([n]1nc2)cc(NC3=CC=CN(C)C3=O)nc1c2C(N)=O HAPOYKFRFWIYAH-UHFFFAOYSA-N 0.000 description 1
- XAPKHCZQASNVPT-UHFFFAOYSA-N CNc([n]1nc2)cc(NC3=CC=CN(C)C3=O)nc1c2C(NC1(CC1)C#N)=O Chemical compound CNc([n]1nc2)cc(NC3=CC=CN(C)C3=O)nc1c2C(NC1(CC1)C#N)=O XAPKHCZQASNVPT-UHFFFAOYSA-N 0.000 description 1
- WWVJGMDXFBEZFL-UHFFFAOYSA-N CNc([n]1nc2)cc(NC3=CC=CN(C)C3=O)nc1c2C(NC1COCC1)=O Chemical compound CNc([n]1nc2)cc(NC3=CC=CN(C)C3=O)nc1c2C(NC1COCC1)=O WWVJGMDXFBEZFL-UHFFFAOYSA-N 0.000 description 1
- NYTDHMPWOJUYAS-PHIMTYICSA-N CNc([n]1nc2)cc(NC3=CC=CN(C)C3=O)nc1c2C(N[C@H](C1)C[C@H]1O)=O Chemical compound CNc([n]1nc2)cc(NC3=CC=CN(C)C3=O)nc1c2C(N[C@H](C1)C[C@H]1O)=O NYTDHMPWOJUYAS-PHIMTYICSA-N 0.000 description 1
- SZEQTPZKAVSXJW-UHFFFAOYSA-N CNc([n]1nc2)cc(NC3=CC=CN(c(cc4)nnc4OC)C3=O)nc1c2C(NC(C1)C1F)=O Chemical compound CNc([n]1nc2)cc(NC3=CC=CN(c(cc4)nnc4OC)C3=O)nc1c2C(NC(C1)C1F)=O SZEQTPZKAVSXJW-UHFFFAOYSA-N 0.000 description 1
- IQWWISIBTSNETG-UHFFFAOYSA-N CNc([n]1nc2)cc(NC3=CC=CN(c4ncccc4)C3=O)nc1c2C(NC1CC1)=O Chemical compound CNc([n]1nc2)cc(NC3=CC=CN(c4ncccc4)C3=O)nc1c2C(NC1CC1)=O IQWWISIBTSNETG-UHFFFAOYSA-N 0.000 description 1
- RYVQBMMDLJTJQG-DZGCQCFKSA-N CNc([n]1nc2)cc(NC3=CC=CN(c4ncccc4)C3=O)nc1c2C(N[C@H](C1)[C@H]1F)=O Chemical compound CNc([n]1nc2)cc(NC3=CC=CN(c4ncccc4)C3=O)nc1c2C(N[C@H](C1)[C@H]1F)=O RYVQBMMDLJTJQG-DZGCQCFKSA-N 0.000 description 1
- AOWWYLCMTZKERE-UHFFFAOYSA-N CNc([n]1nc2)cc(Nc(c(F)c(cc3F)F)c3F)nc1c2C(NC1CC1)=O Chemical compound CNc([n]1nc2)cc(Nc(c(F)c(cc3F)F)c3F)nc1c2C(NC1CC1)=O AOWWYLCMTZKERE-UHFFFAOYSA-N 0.000 description 1
- BDZQXUMDHFWYPC-UHFFFAOYSA-N CNc([n]1nc2)cc(Nc(cc(cc3F)F)c3OC)nc1c2C(N)=O Chemical compound CNc([n]1nc2)cc(Nc(cc(cc3F)F)c3OC)nc1c2C(N)=O BDZQXUMDHFWYPC-UHFFFAOYSA-N 0.000 description 1
- LUCMEHVTEUABDN-UHFFFAOYSA-N CNc([n]1nc2)cc(Nc(cccc3)c3-[n]3nccc3)nc1c2C(NC1CC1)=O Chemical compound CNc([n]1nc2)cc(Nc(cccc3)c3-[n]3nccc3)nc1c2C(NC1CC1)=O LUCMEHVTEUABDN-UHFFFAOYSA-N 0.000 description 1
- WSFMGDCROXKUMH-UHFFFAOYSA-N CNc([n]1nc2)cc(Nc(cccc3)c3OCC(C3)C3NC(c(cn[n]3c(NC)c4)c3nc4Nc3cc(F)cc(F)c3OC)=O)nc1c2C(NC1CC1)=O Chemical compound CNc([n]1nc2)cc(Nc(cccc3)c3OCC(C3)C3NC(c(cn[n]3c(NC)c4)c3nc4Nc3cc(F)cc(F)c3OC)=O)nc1c2C(NC1CC1)=O WSFMGDCROXKUMH-UHFFFAOYSA-N 0.000 description 1
- VNWZIZFJQHUQJH-UHFFFAOYSA-N CNc([n]1nc2)cc(Nc(cccn3)c3OC)nc1c2C(NC1CCC1)=O Chemical compound CNc([n]1nc2)cc(Nc(cccn3)c3OC)nc1c2C(NC1CCC1)=O VNWZIZFJQHUQJH-UHFFFAOYSA-N 0.000 description 1
- SMTKZVHPXIOJKX-UHFFFAOYSA-N CNc([n]1nc2)cc(Nc3c[n](C)nc3C(Nc(cc3)ccc3N(C)CC(C3)C3NC(c(cn[n]3c(NC)c4)c3nc4NC3=CC=CN(c(cc4)nnc4OC)C3=O)=O)=O)nc1c2C(NC1CC1)=O Chemical compound CNc([n]1nc2)cc(Nc3c[n](C)nc3C(Nc(cc3)ccc3N(C)CC(C3)C3NC(c(cn[n]3c(NC)c4)c3nc4NC3=CC=CN(c(cc4)nnc4OC)C3=O)=O)=O)nc1c2C(NC1CC1)=O SMTKZVHPXIOJKX-UHFFFAOYSA-N 0.000 description 1
- PEEAUKXPZHAWOU-UHFFFAOYSA-N CNc([n]1nc2)cc(Nc3c[s]cc3C(O)=O)nc1c2C(NC1CC1)=O Chemical compound CNc([n]1nc2)cc(Nc3c[s]cc3C(O)=O)nc1c2C(NC1CC1)=O PEEAUKXPZHAWOU-UHFFFAOYSA-N 0.000 description 1
- KSTCEBJGNIIDRO-UHFFFAOYSA-N CNc([n]1nc2)cc(Nc3n[n](CC(F)(F)F)cc3)nc1c2C(NC1CC1)=O Chemical compound CNc([n]1nc2)cc(Nc3n[n](CC(F)(F)F)cc3)nc1c2C(NC1CC1)=O KSTCEBJGNIIDRO-UHFFFAOYSA-N 0.000 description 1
- VHDZASRAUXSRAI-UHFFFAOYSA-N Cc1cc(C)cc(Nc(cc(NC)[n]2nc3)nc2c3C(N)=O)c1 Chemical compound Cc1cc(C)cc(Nc(cc(NC)[n]2nc3)nc2c3C(N)=O)c1 VHDZASRAUXSRAI-UHFFFAOYSA-N 0.000 description 1
- UEYHYMKRLINCRR-UHFFFAOYSA-N Cc1cc(C)cc(Nc(cc(NC)[n]2nc3)nc2c3C(NC)=O)c1 Chemical compound Cc1cc(C)cc(Nc(cc(NC)[n]2nc3)nc2c3C(NC)=O)c1 UEYHYMKRLINCRR-UHFFFAOYSA-N 0.000 description 1
- JYYBQGCDHDGPMT-UHFFFAOYSA-N Cc1cc(N(C=CC=C2Nc(cc(NC)[n]3nc4)nc3c4C(NC3CC3)=O)C2=O)n[n]1C Chemical compound Cc1cc(N(C=CC=C2Nc(cc(NC)[n]3nc4)nc3c4C(NC3CC3)=O)C2=O)n[n]1C JYYBQGCDHDGPMT-UHFFFAOYSA-N 0.000 description 1
- YMVXPTQGVVSMDB-UONOGXRCSA-N Cc1ccc(N(C=C(C=C2Nc(cc(NC)[n]3nc4)nc3c4C(N[C@H](C3)[C@H]3F)=O)F)C2=O)nn1 Chemical compound Cc1ccc(N(C=C(C=C2Nc(cc(NC)[n]3nc4)nc3c4C(N[C@H](C3)[C@H]3F)=O)F)C2=O)nn1 YMVXPTQGVVSMDB-UONOGXRCSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802642P | 2019-02-07 | 2019-02-07 | |
| US62/802,642 | 2019-02-07 | ||
| PCT/US2020/017314 WO2020163778A1 (en) | 2019-02-07 | 2020-02-07 | Tyk2 pseudokinase ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210124409A true KR20210124409A (ko) | 2021-10-14 |
Family
ID=71947508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217028660A Ceased KR20210124409A (ko) | 2019-02-07 | 2020-02-07 | Tyk2 슈도키나제 리간드 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220135567A1 (https=) |
| EP (1) | EP3920931A4 (https=) |
| JP (1) | JP2022519696A (https=) |
| KR (1) | KR20210124409A (https=) |
| CN (1) | CN113677347A (https=) |
| AU (1) | AU2020218267A1 (https=) |
| BR (1) | BR112021015616A2 (https=) |
| CA (1) | CA3129438A1 (https=) |
| IL (1) | IL285429A (https=) |
| MX (1) | MX2021009555A (https=) |
| SG (1) | SG11202108619SA (https=) |
| WO (1) | WO2020163778A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019364336B2 (en) | 2018-10-22 | 2023-11-16 | Alumis Inc. | TYK2 inhibitors and uses thereof |
| AU2020247990A1 (en) | 2019-03-26 | 2021-11-11 | Ventyx Biosciences, Inc. | TYK2 pseudokinase ligands |
| KR102938141B1 (ko) | 2019-11-08 | 2026-03-11 | 벤틱스 바이오사이언스, 인크. | Tyk2 슈도키나제 리간드 |
| AU2021345181A1 (en) * | 2020-09-16 | 2023-05-04 | Alumis Inc | Tyk2 inhibitors and uses thereof |
| CN117043164A (zh) * | 2021-01-19 | 2023-11-10 | 安锐生物医药科技(广州)有限公司 | 咪唑并哒嗪或吡唑并嘧啶化合物和组合物 |
| JP2024539280A (ja) | 2021-10-25 | 2024-10-28 | カイメラ セラピューティクス， インコーポレイテッド | Ｔｙｋ２分解剤およびそれらの使用 |
| WO2025061180A1 (zh) * | 2023-09-22 | 2025-03-27 | 杭州多域生物技术有限公司 | 含氮并环类化合物、其药物组合物及其应用 |
| WO2025165746A1 (en) * | 2024-01-30 | 2025-08-07 | Ennovathera, Inc. | Certain chemical entities, compositions, and methods |
| WO2025168035A1 (zh) * | 2024-02-07 | 2025-08-14 | 合肥羿科医药有限公司 | 杂环类化合物、其药物组合物及其应用 |
| WO2025214467A1 (zh) * | 2024-04-12 | 2025-10-16 | 江苏恒瑞医药股份有限公司 | 氨基取代的杂芳环类化合物、其制备方法及其在医药上的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4564485B2 (ja) * | 2003-02-28 | 2010-10-20 | 帝人ファーマ株式会社 | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| CN102271515B (zh) * | 2008-10-31 | 2014-07-02 | 健泰科生物技术公司 | 吡唑并嘧啶jak抑制剂化合物和方法 |
| US10479793B2 (en) * | 2015-11-18 | 2019-11-19 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
| TW201720828A (zh) * | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| JP7160824B2 (ja) * | 2017-03-08 | 2022-10-25 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
| CN110678467B (zh) * | 2017-05-22 | 2023-06-13 | 豪夫迈·罗氏有限公司 | 治疗化合物和组合物及其使用方法 |
| KR102717819B1 (ko) * | 2017-07-28 | 2024-10-14 | 다케다 야쿠힌 고교 가부시키가이샤 | Tyk2 억제제 및 이의 용도 |
| JP7179161B2 (ja) * | 2018-09-10 | 2022-11-28 | イーライ リリー アンド カンパニー | 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体 |
| JP7619951B2 (ja) * | 2018-10-15 | 2025-01-22 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| TWI800696B (zh) * | 2018-12-10 | 2023-05-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物 |
| KR102938141B1 (ko) * | 2019-11-08 | 2026-03-11 | 벤틱스 바이오사이언스, 인크. | Tyk2 슈도키나제 리간드 |
-
2020
- 2020-02-07 US US17/428,953 patent/US20220135567A1/en not_active Abandoned
- 2020-02-07 BR BR112021015616A patent/BR112021015616A2/pt not_active Application Discontinuation
- 2020-02-07 KR KR1020217028660A patent/KR20210124409A/ko not_active Ceased
- 2020-02-07 EP EP20752194.9A patent/EP3920931A4/en not_active Withdrawn
- 2020-02-07 JP JP2021546005A patent/JP2022519696A/ja active Pending
- 2020-02-07 AU AU2020218267A patent/AU2020218267A1/en not_active Abandoned
- 2020-02-07 CA CA3129438A patent/CA3129438A1/en active Pending
- 2020-02-07 MX MX2021009555A patent/MX2021009555A/es unknown
- 2020-02-07 SG SG11202108619SA patent/SG11202108619SA/en unknown
- 2020-02-07 CN CN202080026979.3A patent/CN113677347A/zh active Pending
- 2020-02-07 WO PCT/US2020/017314 patent/WO2020163778A1/en not_active Ceased
-
2021
- 2021-08-08 IL IL285429A patent/IL285429A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3920931A1 (en) | 2021-12-15 |
| US20220135567A1 (en) | 2022-05-05 |
| SG11202108619SA (en) | 2021-09-29 |
| CA3129438A1 (en) | 2020-08-13 |
| BR112021015616A2 (pt) | 2021-11-09 |
| MX2021009555A (es) | 2021-10-13 |
| AU2020218267A1 (en) | 2021-09-30 |
| EP3920931A4 (en) | 2022-08-10 |
| IL285429A (en) | 2021-09-30 |
| JP2022519696A (ja) | 2022-03-24 |
| CN113677347A (zh) | 2021-11-19 |
| WO2020163778A1 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20210124409A (ko) | Tyk2 슈도키나제 리간드 | |
| KR102938141B1 (ko) | Tyk2 슈도키나제 리간드 | |
| JP7595582B2 (ja) | Ｔｙｋ２偽キナーゼリガンド | |
| KR102916168B1 (ko) | Jak 억제제 | |
| JP2022549435A (ja) | Ｊａｋ阻害剤 | |
| KR20220051351A (ko) | Jak 억제제 | |
| HK40066192A (zh) | Tyk2假激酶配体 | |
| HK40066192B (zh) | Tyk2假激酶配体 | |
| HK40080028B (zh) | Tyk2假激酶配体 | |
| HK40064378A (en) | Tyk2 pseudokinase ligands | |
| HK40080028A (en) | Tyk2 pseudokinase ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20210907 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20250210 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20250627 Comment text: Decision to Refuse Application Patent event code: PE06012S01D |